How big is Repare Therapeutics, Inc.?

As of Jun 18, Repare Therapeutics, Inc. has a market capitalization of 60.91 million, with net sales of 1.07 million and a net profit of -127.89 million over the last four quarters. The company's shareholder's funds are 151.13 million, and total assets are 176.51 million.

Market Cap: As of Jun 18, Repare Therapeutics, Inc. has a market capitalization of 60.91 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Repare Therapeutics, Inc. reported net sales of 1.07 million and a net profit of -127.89 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company's shareholder's funds amounted to 151.13 million, while total assets were reported at 176.51 million.

What does Repare Therapeutics, Inc. do?

Repare Therapeutics, Inc. is a precision oncology company focused on targeting tumor vulnerabilities in genetically defined patient populations. It has a market cap of approximately $60.91 million and reported a net profit loss of $30 million as of March 2025.

Overview: <BR>Repare Therapeutics, Inc. is a precision oncology company that targets specific vulnerabilities of tumors in genetically defined patient populations within the Pharmaceuticals & Biotechnology industry, classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Profit: -30 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 60.91 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.98 <BR>Return on Equity: -98.52% <BR>Price to Book: 0.49 <BR><BR>Contact Details: <BR>Address: 7210 Frederick-Banting, Suite 100, ST-LAURENT QC : H4S 2A1 <BR>Website: http://www.reparerx.com/

Should I buy, sell or hold Repare Therapeutics, Inc.?

Who are in the management team of Repare Therapeutics, Inc.?

As of March 2022, the management team of Repare Therapeutics, Inc. includes Mr. Lloyd Segal (CEO), Mr. Jerel Davis (Chairman), and several independent directors, including Dr. David Bonita, Mr. Todd Foley, Dr. Samarth Kulkarni, Dr. Briggs Morrison, and Mr. Kevin Raidy. This team provides governance and strategic direction for the company.

As of March 2022, the management team of Repare Therapeutics, Inc. includes the following individuals:<BR><BR>- Mr. Jerel Davis, Independent Chairman of the Board<BR>- Mr. Lloyd Segal, President, Chief Executive Officer, and Director<BR>- Dr. David Bonita, Independent Director<BR>- Mr. Todd Foley, Independent Director<BR>- Dr. Samarth Kulkarni, Independent Director<BR>- Dr. Briggs Morrison, Independent Director<BR>- Mr. Kevin Raidy, Independent Director<BR><BR>This team comprises a mix of executive leadership and independent directors, contributing to the governance and strategic direction of the company.

Is Repare Therapeutics, Inc. overvalued or undervalued?

As of August 8, 2025, Repare Therapeutics, Inc. has deteriorated from a risky to a non-qualifying valuation grade due to significant overvaluation and poor financial metrics, including a Price to Book Value of 0.50 and a negative return on equity of -98.52%, alongside a troubling stock performance with a one-year return of -46.84% compared to the S&P 500's 17.14%.

As of 8 August 2025, the valuation grade for Repare Therapeutics, Inc. has moved from risky to does not qualify, indicating a significant deterioration in its investment appeal. The company is overvalued based on its current financial metrics, particularly given its Price to Book Value of 0.50 and an EV to EBITDA ratio of 0.47, which suggest that the market is not pricing in the company's substantial losses and negative returns on equity of -98.52%. In comparison, PetIQ, Inc. shows a fair valuation with a P/E ratio of 27.10, highlighting the stark contrast in market perception between these two companies.<BR><BR>Repare's recent stock performance has been troubling, with a one-year return of -46.84% compared to the S&P 500's 17.14%, and a staggering decline of -94.65% over the past five years, while the S&P 500 has gained 96.61% in the same period. This underperformance reinforces the notion that Repare Therapeutics is not only struggling operationally but is also being viewed unfavorably by the market.

Is Repare Therapeutics, Inc. technically bullish or bearish?

As of September 4, 2025, Repare Therapeutics, Inc. shows a bullish technical trend with positive short-term momentum, despite underperforming the S&P 500 over the past year and three years, but outperforming it year-to-date.

As of 4 September 2025, the technical trend for Repare Therapeutics, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish, and daily moving averages also indicate a bullish stance. However, the monthly MACD is only mildly bullish, and Bollinger Bands show a mildly bearish signal on the monthly timeframe. The KST and Dow Theory are both bullish on the weekly and mildly bullish on the monthly. <BR><BR>In terms of performance, the stock has underperformed the S&P 500 over the past year and three years, with returns of -46.84% and -85.90%, respectively, compared to the S&P 500's 17.14% and 70.41%. However, it has outperformed the benchmark year-to-date with a return of 34.73% versus 12.22% for the S&P 500. Overall, the current technical stance is bullish, indicating a positive momentum in the short term.